Eli Lilly is selling Zepbound directly to consumers via its LillyDirect platform, offering significant discounts but requiring out-of-pocket payments as most health insurers do not cover the drug, exacerbating affordability issues for many potential users.

Amgen has launched two pivotal late-stage trials for MariTide, an experimental weight loss drug aimed at entering the growing obesity treatment market, competing against other products from Novo Nordisk and Eli Lilly.